GlassScriptPhysician profile
Troy W Geyman
NPI 1407847379
$1,468.11
in general payments reported to CMS, 2019-2025
27 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $247 · 2021: $347 · 2022: $183 · 2023: $214 · 2024: $178 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $543.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $543.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $197.19 | 2020-2025 | Ozempic, Rybelsus, Tresiba |
| Pfizer INC. | $172.54 | 2019-2024 | |
| Lundbeck LLC | $128.77 | 2022-2023 | Rexulti |
| Abbvie INC. | $128.66 | 2022-2024 | |
| Lilly USA, LLC | $86.57 | 2019-2025 | Mounjaro |
| Glaxosmithkline, LLC. | $85.21 | 2020-2024 | Shingrix |
| Biohaven Pharmaceuticals, INC. | $68.41 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.85 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $56.40 | 2019-2020 | |
| Amgen INC. | $53.10 | 2021-2022 | |
| Horizon Therapeutics Plc | $50.52 | 2019-2021 | |
| Mylan Specialty L.P. | $45.37 | 2021-2023 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $41.86 | 2023-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.87 | 2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $33.40 | 2024-2025 | Cobenfy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $29.49 | 2022 | |
| Boston Scientific Corporation | $23.61 | 2025 | Watchman Flx |
| Eisai INC. | $20.55 | 2020 | |
| Neurocrine Biosciences, INC. | $20.38 | 2025 | |
| Supernus Pharmaceuticals, INC. | $18.27 | 2021 | |
| Merck Sharp & Dohme LLC | $18.27 | 2024 | Capvaxive, Vaxelis, Gardasil 9 |
| Exact Sciences Corporation | $17.25 | 2023 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $17.19 | 2022 | |
| Upsher-Smith Laboratories LLC | $17.12 | 2020 | |
| Astellas Pharma US INC | $15.32 | 2023 | Veozah |
| Grifols USA, LLC | $15.02 | 2020 | |
| Genzyme Corporation | $12.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Geyman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.